Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review

Schmid, Sabine; Omlin, Aurelius; Blum, David; Strasser, Florian; Gillessen, Silke; Rothermundt, Christian

doi:10.1093/annonc/mdv326

Cited by 10 publications

(4 citation statements)

References 254 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is defined as a prostate cancer that progresses biologically, clinically or on imaging studies in the face of castrate testosterone levels (< 50ng/ml). Many proposed mechanisms explain the development of androgen resistance, and strategies are being developed to overcome this problem (19). There was a consensus among panelists (79%) that there is no need to add an antiandrogen to the prevailing androgen deprivation therapy to define hormone resistance (question 10).…”

Section: Resultsmentioning

confidence: 99%

Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review

et al. 2019

View full text Add to dashboard Cite

Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. In Brazil, it is likewise the second most common cancer among men, second only to non-melanoma skin cancers.The aim of this consensus is to align different opinions and interpretations of the medical literature in a practical and patient-oriented approach. The first Brazilian Consensus on the Treatment of Advanced Prostate Cancer was published in 2017, with the goal of reducing the heterogeneity of therapeutic conduct in Brazilian patients with metastatic prostate cancer. We acknowledge that in Brazil the incorporation of different technologies is a big challenge, especially in the Sistema Único de Saúde (SUS), which allows for the disparity in the options available to patients treated in different institutions. In order to update the recommendations and to make them objective and easily accessible, once more a panel of specialists was formed in order to discuss and elaborate a new Brazilian Consensus on Advanced Prostate Cancer. This Consensus was written through a joint initiative of the Brazilian Society of Clinical Oncology (SBOC) and the Brazilian Society of Urology (SBU) to support the clinical decisions of physicians and other health professionals involved in the care of patients with prostate cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Eleven patients experienced an early high rise of CGA, which was correlated with PFS and OS. Circulating CGA was used as objective tumor biology assessment tool in five trials including >500 patients with mCRPC in total according to a recent review (25). A high rise has not been studied in these trials.…”

Section: Discussionmentioning

confidence: 99%

Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel

Hardenberg

Schwartz

Werner

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Objective assessments of bone metastases in clinical trials have historically included serial imaging with standard techniques such as CT and bone scintigraphy; however, the clinical significance of changes in size or intensity of bone metastases, particularly on a bone scan, is difficult to interpret [57–59].…”

Section: Assessment Of Bone-metastatic Diseasementioning

confidence: 99%

The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone

Hussain

Lee

Graff

et al. 2019

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Bone metastases are a frequent complication of solid tumors, leading to significant skeletal sequelae that negatively impact quality of life and survival. Prevention and management of skeletal-related complications are critical treatment goals in oncology. Endpoints used in clinical trials to evaluate skeletal-related complications have evolved. In contrast to single measures of bone health, contemporary clinical trial endpoints reflect composite measures of skeletal-related complications, and increasingly also survival. In addition, key symptomatic components, which are more reflective of quality of life and the patient experience, are being incorporated. Given the evolution and resulting diversity of the endpoints being used in pivotal trials, it is becoming increasingly relevant to clarify the utility and the potential clinical impact of these measures not only within the context of trials but also in the real-world setting. Here, we describe the development and evolution of skeletal endpoints used in trials, and discuss their clinical relevance.

show abstract

Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review

Cited by 10 publications

References 254 publications

Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review

Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review

Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel

The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone

Contact Info

Product

Resources

About